NVIDIA Introduces New Software Tools for Biopharma AI Applications

by Andrii Buvailo, PhD          Biopharma insight

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   904    Comments 0
Topics: Industry Trends   
Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email   |  

NVIDIA's CEO, Jensen Huang, recently outlined the company's expanded focus on software solutions designed to facilitate the adoption of artificial intelligence (AI) in the biopharmaceutical sector, beyond its well-established position as a leading hardware manufacturer.

As Endpoints News reports, during a keynote speech at the annual NVIDIA developer's conference, held at the SAP Center in San Jose, California, Huang highlighted the pivotal role of healthcare in what he described as a new industrial revolution powered by generative AI.

Among the key innovations introduced was Nvidia NIM (Nvidia Inference Microservices), a suite of ready-to-use AI models tailored for various tasks within drug research and development.

These models, including the small molecule generator MolMIM and the protein-ligand structure predictor DiffDock, are designed to be highly accessible and easy to integrate into biopharma companies' existing workflows. Nvidia offers these microservices at two pricing options: a yearly fee of $4,500 per GPU for on-premises use or an hourly cloud-based rate of $1 per GPU.

Huang emphasized the significance of Nvidia NIM as part of Nvidia's broader strategy to become what he termed "an AI foundry." This strategy includes other key components such as NeMo, a generative AI framework with a version specifically for biology called BioNeMo, and DGX Cloud, which provides remote access to Nvidia's supercomputing resources.

The introduction of NVIDIA NIM has a potential to address a critical challenge in the drug development industry: the difficulty of integrating sophisticated AI models like Google DeepMind's AlphaFold into practical research workflows. While AlphaFold's ability to predict protein structures has been heralded as a major advance, pharmaceutical companies often struggle to tailor these models to their specific needs and to support them with the necessary computational infrastructure.

RELATED: Denmark Collaborates with NVIDIA to Establish AI Innovation Centre Featuring Advanced Supercomputer

Nvidia's new microservices model aims to simplify this process by allowing companies to "take their microservices with them," enabling flexible deployment options across cloud-based and on-premises computing environments. This approach also offers the advantage of keeping proprietary data within the company's own security perimeter, a feature that Nvidia's Vice President of Healthcare, Kimberly Powell, highlighted as a significant benefit in terms of control and flexibility.

Nvidia's shift toward software-centric solutions represents a strategic move to broaden its impact in the pharmaceutical sector. Through these initiatives, Nvidia aims to make advanced AI technologies more accessible and practical for drug development companies, potentially accelerating the pace of innovation in the field.

Topics: Industry Trends   

Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email


There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *